Peregrine Pharmaceuticals has presented a range of clinical, translational, and pre-clinical study results of bavituximab, an investigational phosphatidylserine (PS)-signalling pathway inhibitor.

According to the firm, the study results demonstrated that bavituximab has promoted anti-tumour T cell activity in several tumour types.

Preclinical data showed that combining the enhanced T cell anti-tumour activity of bavituximab-like antibodies with checkpoint inhibitors, such as anti-PD-1 antibodies results in better tumour control in multiple models of cancer.

Peregrine Pharmaceuticals preclinical research vice-president Jeff Hutchins said: "We continue to generate a broad collection of pre-clinical, translational and clinical data highlighting bavituximab’s novel mechanism of action and synergistic activity for a range of combination treatments."

"We continue to generate a broad collection of pre-clinical, translational and clinical data highlighting bavituximab’s novel mechanism of action."

The study also showed that bavituximab-like antibodies significantly increase the prevalence of tumour infiltrating CD8+ T-cells and immune-activating cytokines, while decreasing macrophages and myeloid cells that allow the tumour to evade immune detection.

The data of translational study across multiple cancers suggested that tumours with low PD-L1 or PD-1 expression on tumour infiltrating T cells showed promising signs of immune activation after treatment with bavituximab.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

The elucidation and confirmation of bavituximab’s mechanism of action represents the potential of bavituximab to enhance the anti-tumour effects of both chemotherapy and immune checkpoint inhibitors.

In addition, the combination of bavituximab-like antibodies and anti-PD-1 antibodies resulted in enhanced and synergistic anti-tumour activity in animal models of multiple tumour types compared to either agent alone.

Results from several clinical and preclinical studies in a range of tumour types demonstrated that bavituximab and bavituximab-like antibodies, in combination with conventional therapy, have consistently showed estimated survival curves that plateau.

Clinical Trials Arena Excellence Awards - Have you nominated?

Nominations are now open for the prestigious Clinical Trials Arena Excellence Awards - one of the industry's most recognised programmes celebrating innovation, leadership, and impact. This is your chance to showcase your achievements, highlight industry advancements, and gain global recognition. Don't miss the opportunity to be honoured among the best - submit your nomination today!

Nominate Now